Monopar Announces Successful Advancement of Camsirubicin Phase 1b Clinical Trial Past Fourth Cohort, Escalates Next to 650mg/m2

January 18, 2023

https://www.globenewswire.com/news-release/2023/01/18/2590784/0/en/Monopar-Announces-Successful-Advancement-of-Camsirubicin-Phase-1b-Clinical-Trial-Past-Fourth-Cohort-Escalates-Next-to-650mg-m2.html

WILMETTE, Ill., Jan. 18, 2023 (GLOBE NEWSWIRE) — Monopar Therapeutics Inc. (Nasdaq:MNPR), a clinical-stage biopharmaceutical company focused on developing proprietary therapeutics designed to extend life or improve the quality of life for cancer patients, today announced the positive recommendation from its safety review committee to advance to the fifth dose level (650 mg/m2) in its camsirubicin Phase 1b trial in patients with advanced soft tissue sarcoma (ASTS). This decision was made following a review of safety data from the patients in the first four dose cohorts.

Read more at globenewswire.com

Related news for (MNPR)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.